A phase 1 safety and immunogenicity study of the Pharmexa-Epimmune HIV-1 CTL epitope-based DNA vaccine (EP HIV-1090) administered using a Biojector 2000 needle free immunization device in HIV-1 infected individuals receiving potent combination antiretroviral therapy (ART)

Trial Profile

A phase 1 safety and immunogenicity study of the Pharmexa-Epimmune HIV-1 CTL epitope-based DNA vaccine (EP HIV-1090) administered using a Biojector 2000 needle free immunization device in HIV-1 infected individuals receiving potent combination antiretroviral therapy (ART)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2007

At a glance

  • Drugs EP 1090 (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Epimmune
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Dec 2007 Status changed from recruiting to in progress. Updated from ClinicalTrials.gov.
    • 31 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top